Clinical trial NCT01655407: Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds
Official title: Evaluation of Autologous Engineered Skin Substitute (ESS-W) Compared to Meshed, Split-Thickness Autograft (AG) for Treatment of Deep Partial- and Full-Thickness Thermal Burn Wounds in Adult Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Thermal Injury
Deep Partial-Thickness Burn
Full-Thickness Burn
Keywords: Split-thickness Autograft
Engraftment
Wound Closure
Engineered Skin Substitute
ESS-W
Cultured Skin Substitutes
Burn
Lead sponsor: Amarantus BioScience Holdings, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Amarex Clinical Research
First posted: 2012-08-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds.

The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Detailed description: This study is designed to evaluate the safety and efficacy of autologous engineered skin substitute (ESS-W) compared to conventional split-thickness AG for the treatment of extensive, deep partial- and full-thickness thermal burns. A matched and randomized burn site format will be used to evaluate the successful graft take on excised deep partial- and full-thickness burns when grafted with either 1) unmeshed ESS-W or 2) meshed AG (the current standard treatment of split thickness AG).

This research study is divided into five study periods: (1) Screening Period of up to one week and (2) Pre-Grafting Period, which will last approximately 35-45 days, (3) Grafting Day(s), which are the day(s) on which grafts are applied (i.e., First Graft: Day 0 and the optional subsequent Grafting Day i.e., Second Graft: Day 0), (4) Post Grafting Observation Period, which begins with 28 days follow-up after each Grafting Day(s), and continues till Post-Operative Month (POM) 6 from the last Grafting Day, and (5) Anecdotal Observation Period

Eligibility criteria: Inclusion Criteria:

* Has deep partial or full-thickness thermal burns ≥50% of the TBSA and fulfills the total grafting area requirement ranging from 288 cm2 up to 5,600 cm2, divided between two (or more) recipient sites.
* Is expected to require multiple skin grafting procedures.
* Is ≥18 years and ≤40 years of age at the time of enrollment.
* Females of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use appropriate birth control methods during the pre-grafting period and for three months following the last Grafting Day.
* Subject (or a legally authorized representative (LAR)) has provided written informed consent for study participation and procedures to be performed.

Exclusion Criteria:

* Has a current diagnosis of septic shock or Multiple Organ Dysfunction Syndrome, which in the opinion of the Investigator would put the potential subject at risk of serious morbidity or death by participating in the study.
* Has a current diagnosis of an invasive burn wound infection in unexcised burn wound.
* Is pregnant.
* Is a prisoner at the time of obtaining written informed consent.
* Has a documented history of allergy or sensitivity to any of the antimicrobials or reagents used in preparation and application of ESS-W including the irrigation solution used before and after grafting. These include aminoglycosides, polymyxin B, mupirocin, ciprofloxacin, amphotericin B, hydrocortisone, and insulin.
* Has a documented history of allergy or sensitivity to any of the animal products used in preparation of ESS-W. These products include bovine blood, bovine collagen, bovine collagenase, and porcine trypsin-versene.
* Has a documented history of allergy or sensitivity to glycosaminoglycan, the polymer component of ESS-W.
* Has a documented ongoing condition which could delay wound healing such as insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic hepatic dysfunction (Child-Pugh class B or C).
* Has a severe malnutrition or other concomitant illness which, in the opinion of the Investigator, has the potential to significantly delay wound healing.

Primary outcomes:
measure: Incidence and severity of infections at grafting sites
timeFrame: Up to Month 6 after the last grafting day
measure: Incidence of re-grafting
timeFrame: Up to Month 6 after the last grafting day
measure: Incidence of adverse events that are related to study treatment and associated with the grafting site
timeFrame: Up to Month 36 after the last grafting day
measure: Incidence of all adverse events.
timeFrame: Up to Month 36 after the last grafting day
measure: Percentage engraftment as determined by the Investigator through clinical assessment
timeFrame: Up to Month 3 after the last grafting day
measure: Percentage engraftment as determined by an independent observer through clinical assessment
timeFrame: Up to Month 3 after the last grafting day
measure: Confirmation of engraftment by histological assessment
timeFrame: Up to Month 6 after the last grafting day
measure: Percentage of wound closure as determined by blinded computerized planimetric assessment
timeFrame: Up to Month 3 after the last grafting day
measure: Percentage area of re-grafting as determined by blinded computerized planimetric assessment
timeFrame: Up to Month 6 after the last grafting day
Secondary outcomes:
measure: Scar outcome assessment using the modified Vancouver Scar Scale (mVSS).
timeFrame: Up to Month 36 after the last grafting day
measure: Incidence and severity of post-burn pruritus utilizing a validated patient self-assessment instrument
timeFrame: Up to Month 36 after the last grafting day
measure: Incidence of contracture release or revision surgeries
timeFrame: Up to Month 36 after the last grafting day
measure: Incidence of increased temperature sensitivity
timeFrame: Up to Month 36 after the last grafting day
measure: Incidence of paresthesias, pain, dulling of sensation assessed through patient self-reporting scale and by monofilament testing
timeFrame: Up to Month 36 after the last grafting day
Other outcomes:
Locations:
city: Pheonix
country: United States
facility: Arizona Burn Center
state: Arizona
city: Houston
country: United States
facility: US Army Institute of Surgical Research
state: Texas
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
Study officials:
affiliation: The Arizona Burn Center
name: Michael Peck, MD
role: STUDY_DIRECTOR
References: